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Abstract
Background:  An association between mumps-measles-rubella (MMR) vaccination and the onset
of symptoms typical of autism has recently been suggested. This has led to  considerable concern
about the safety of the vaccine.
Methods:  A matched case-control study using data derived form the United Kingdom  General
Practice Research Database. Children with a possible diagnosis of  autism will be identified from
their electronic health records. All diagnoses  will be validated by a detailed review of hospital
letters and by using  information derived from a parental questionnaire. Ten controls per case will
be selected from the database. Conditional logistic regression will be used to  assess the association
between MMR vaccination and autism. In addition case  series analyses will be undertaken to
estimate the relative incidence of onset  of autism in defined time intervals after vaccination. The
study is funded by  the United Kingdom Medical Research Council.
Discussion:  Electronic health databases  offer tremendous  opportunities  for  evaluating   the
adverse effects of vaccines. However there is much scope for bias and  confounding. The rigorous
validation of all diagnoses and the collection of  additional information by parental questionnaire in
this study are essential to  minimise the possibility of misleading results.
Background
The epidemiology of autism
Autism is a pervasive developmental disorder character-
ised by abnormalities  in the development of language,
communication abilities, and social  interactions and by
a pattern of restricted play and behaviour which tends to
be highly repetitive, unimaginative and rigid [1]. By  def-
inition, the abnormalities must be present by the age of
three years,  although the diagnosis is usually not made
until the age of four or five years  [2]. In studies of the
consistency of diagnosis there has  been a high consensus
between psychiatrists and coding instruments [3].
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The age at which parents first recognise an abnormality
is variable, with  40% of autistic children having shown
typical features by the age of one year  and most by the
age of two years[4]. This age is  influenced by the degree
of associated mental retardation and birth order (the
less severe and first born children tending to have later
age of parental  recognition) [5]. Most population-based
studies have  found a prevalence of autism between 5 and
10 per 10,000 children [6].
MMR vaccination and autism
In 1998 a link was suggested between mumps-measles-
rubella (MMR) vaccination  and autism [7]. This was
based on an uncontrolled case  series of 12 children re-
ferred to a paediatric gastroenterology unit with a  histo-
ry of normal development followed by loss of acquired
skills, including  language, together with diarrhoea and
abdominal pain. It was suggested that the  gastrointesti-
nal and developmental symptoms were a syndrome that
could have  been triggered by MMR vaccination. The
study was widely criticised [8,9] but generated consider-
able media  interest [10] and led to a small fall in MMR
coverage in  the United Kingdom [11]. A larger case series
of 60  children with the same combination of clinical
findings has recently been  published [12].
Since the first study by Wakefield et al, a number of pub-
lished studies have  looked specifically at this issue. In a
small study from Finland, among 31  children who had
reported a gastrointestinal adverse reaction to MMR
vaccination, none had subsequently developed signs of
autism [13]. A similar larger study looked at all notified
serious adverse  events following MMR vaccination in
Finland over a 14 year period [14]. There were no new
cases of autism among 173 notified  adverse events. How-
ever such routine passive surveillance systems have a
number  of weaknesses for epidemiological studies [15].
There is  no control group, the quality of the data may be
suboptimal and detecting an  effect depends entirely on
clinicians believing a new illness was due to  vaccination.
In Sweden no increase was apparent in the incidence of
autism  following the introduction of MMR vaccination
[16]. Both  these studies included small numbers of chil-
dren with autism and had limited  ability to assess the
link between MMR vaccine and autism. The United
Kingdom  Committee on Safety of Medicines set up a
working party to assess parental and  medical reports of
children who had developed autism, Crohn's disease or
similar disorders following MMR vaccination. The
Working Party Report was, by  its own description, solely
a descriptive account of those children whose  parents
had sought legal advice about possible vaccine damage
[17]. The Report highlighted bias in the way affected chil-
dren were  selected for inclusion in the study and the lack
of any control group before  concluding that they could
not prove or refute the suggested associations  between
MMR vaccine and autism. A single large high quality ep-
idemiological  study has been published [18]. This study
included 293  children with confirmed autism from
North Thames health districts. From time  series trends
analysis, age of diagnosis in vaccinated and unvaccinated
groups  and a case series analysis, the authors concluded
there was no evidence to  support an association. The
study did find a positive association between MMR  vac-
cination and first parental concerns in the first six
months following  vaccination. Although the authors
considered that this finding was likely to be  either a
chance finding or due to inaccuracy in recalling the date
of onset of  symptoms, this interpretation has been dis-
puted [19]. It  was also suggested that because the study
only considered relatively short risk  periods after vacci-
nation, a causal link may have been missed [20]. The au-
thors of the study have undertaken a re-analysis looking
at  longer post vaccination risk periods, and again found
no evidence to support a  link between MMR vaccination
and autism (Farrington CP, personal  communication).
In the light of continuing concern about the proposed
link between MMR  vaccination and autism
[21,22,23,24,25,26] we plan to undertake a case-control
study using  data derived form the General Practice Re-
search Database.
Objectives
The study has two linked objectives with respect to MMR
vaccination. Firstly  to determine if autistic children are
more likely to have received MMR vaccine  prior to dis-
ease onset. Secondly to examine whether there is any as-
sociation  between clinical onset of disease and the
timing of MMR vaccination.
Materials and methods
The General Practice Research Database (GPRD)
The GPRD (previously known as the VAMP Research
Bank) was set up in 1987 and  is now held by the Medi-
cines Control Agency [27,28]. It contains complete pre-
scribing and diagnostic  information from a large
number of general practices and is the largest source  of
continuous data on illness and prescribing habits in the
United Kingdom.  Over 200 published studies have been
completed using the database.  Participating general
practitioners were given instruction over a 12-month  pe-
riod regarding standardised recording of clinical infor-
mation into their  computing systems. The general
practices are broadly representative of all  practices in
the United Kingdom in terms of geographical distribu-
tion and size  and the age and sex distributions of the
population included in the GPRD are  similar to the
whole United Kingdom population [29]. The  data avail-
able directly from the database include all drug prescrip-BMC Public Health (2001) 1:2 http://www.biomedcentral.com/1471-2458/1/2
tions and  their indication, a record of every consultation
and of every diagnosis. The  data collected is audited reg-
ularly and the participating general practices are  sub-
jected to a number of quality checks. Of the practices
contributing to the  database, about 280 practices, with a
combined population of around 2.1 million  patients cur-
rently pass these rigorous quality checks. The quality of
the  information in the database has been validated in a
number of independent  studies and has been found to be
high [30,31,32,33,34,35].
The general practitioners keep all referral letters, hospi-
tal discharge  summaries and other clinically relevant
letters in a manual file. In addition  to the electronic
health record, questionnaires can be sent to patients (or
their parents) via general practitioners, and copies of let-
ters relating to  referrals and hospital care can be ob-
tained. The data are held anonymously in  the central
GPRD database, with patient identifiers removed.
Identification of affected children
Children with putative autism will be identified by
searching the whole  electronic record of all people in-
cluded in the GPRD for diagnostic codes which  possibly
relate to a diagnosis of autism. MMR vaccine was intro-
duced in the  United Kingdom for all children aged 12 to
15 months in October 1988. An MMR  catch-up cam-
paign was also launched for older children in 1988. We
will  separately identify those children with putative au-
tism born after and before  mid-1987, which separates
out those children likely to have received the MMR  vac-
cine around the age of 1 year and those likely to have re-
ceived it at a  later date. Separate analyses will be
conducted on these two groups. Although  all major past
diagnoses are recorded in practice computers when new
patients  register with practices, such recording may be
incomplete. To overcome this  potential problem, we will
identify children first diagnosed when they were  regis-
tered with practices participating in the GPRD. Children
diagnosed prior  to registration with the GPRD will be
analysed separately with their matched  controls. The re-
sults from these two groups will be pooled if they are
similar.
Identification and selection of controls
For each affected child we will sample two groups of
matched controls from  the GPRD. The first group will
consist of five people with no record of autism  matched
on age (±  one year), sex and practice. Matching is this
group aims  to control for possible confounding by the
general practice with which  participants are registered.
The second group will be of similar size and will  be
matched on age and sex but not on practice, to avoid the
possibility of  overmatching. For children diagnosed
while registered with a GPRD practice, the  date of diag-
nosis will be called the index date. The controls will be
selected  from those patients registered with the GPRD
on the index date of the affected  child to whom they are
matched. We will not be able to apply the same method
for selecting controls for children with autism diagnosed
prior to registering  with a practice participating in the
GPRD because they will not have an index  date. There-
fore the matched controls for children diagnosed prior to
registering with a practice participating in the GPRD will
be selected from all  patients registered with the GPRD
on the date the affected child registered  with the GPRD.
Questionnaire to parents of affected children and controls
Subject to ethical approval, a questionnaire will be sent
to the parents of all affected children and to  two controls
per affected child, one matched on practice and one not
matched on  practice and closest in age to the affected
child. The questionnaire to parents  of children with au-
tism will include an autism screening questionnaire[36]
and will solicit information on: the date of first  symp-
toms of autism and earliest date of parental concern
about symptoms  possibly related to autism; the educa-
tional status of the child; the knowledge  and beliefs of
parents regarding the causes of autism; and family histo-
ry of  pervasive developmental problems. In addition the
questionnaire will  specifically ask about family history
of pervasive developmental problems,  genetic disorders
and about regression (loss of skills) allowing us to classi-
fy  affected children into those with reported regression
and those with no  regression.
For both affected children and controls the question-
naire will include  questions about: the socioeconomic
status of the parents; birth order and  family size; history
of bowel disturbance in the child; and vaccination  histo-
ry.
Diagnosis: definition and validation
As a first step to validate the diagnoses, copies of all hos-
pital summaries  will be requested from the GPs con-
cerned. Previous studies using the GPRD have  obtained
full copies of hospital summaries on over 90% of patients
still  registered with a collaborating practices [35,37]. We
will obtain copies of letters relating to both autism  and
to all other reasons for hospital investigation or attend-
ance, including  bowel investigations and inflammatory
bowel disease (see below). The basis for  the diagnosis of
autism, evidence of associated genetic disorders and the
date  of first attendance for possible autism will be ex-
tracted from the records.
There is strong agreement among child psychiatrists
about concepts of and  operational definitions for autism
[3]. We believe that  no child will be labelled as autistic in
the GP record without referral to  child psychiatry servic-BMC Public Health (2001) 1:2 http://www.biomedcentral.com/1471-2458/1/2
es. Two studies have specifically documented the  com-
pleteness of the information in the GPRD about referrals
occurring and their  outcome [30,31].
All information about children possibly affected by an
autistic spectrum  disorder, including information about
the current educational status of the  child from the ques-
tionnaire, will be reviewed independently by two child
psychiatrists. They will use DSM-IV / ICD 10 research di-
agnostic criteria to  define autistic spectrum disorders,
and will attempt to subtype the disorders  according to
their phenomenology. In particular they will separate
and  sub-classify autistic disorder in DSM-IV or child-
hood autism in ICD-10,  Asperger's disorder, atypical au-
tism / pervasive developmental disorder not  otherwise
specified, and other forms of pervasive developmental
disorders (i.e.  Rett's syndrome and childhood disinte-
grative disorder). This will be achieved  by rating the de-
velopmental abnormalities on a symptom basis and then
applying  diagnostic algorithms. They will also make an
overall global judgement about  the clinical pattern and
rate their confidence in this final diagnostic  judgement
in order to allow for difficult or improbable diagnoses to
be treated  separately. Inter-rater reliability estimates
will result from this exercise.  Separate analyses will be
carried out for children with a definite diagnosis  and for
children with a definite or probable diagnosis in order to
assess the  potential impact of misclassification.
Exclusion of affected children with an alternative aetiolo-
gy
Inclusion of affected children who have an established
alternative aetiology  may bias the estimated odds ratio
for the association between vaccination and  adverse out-
come towards unity [38]. Some children will  have med-
ical disorders thought to have a causal association with
autism  (fragile X disorder, tuberous sclerosis, phenylke-
tonuria, congenital rubella)  and will be excluded. A re-
cent review estimated that this will lead to the  exclusion
of at most 6% of affected children [6].
Determination of date of onset
From the GP record, hospital letters and parental ques-
tionnaire for each  affected child we will extract the date
of:
• first attendance to the GP with symptoms or problems
potentially  relating to a future diagnosis of autism, such
as behavioural difficulties  (e.g. sleeping or eating diffi-
culties), delay in motor development and  milestones,
delay in language development, abnormalities in social
development  (for example delayed smiling, lack of reci-
procity, lack of anticipation, odd  behaviours);
• first concerns or symptoms as recorded in the hospital
letters;
• definitive diagnosis from the hospital letters;
• first parental concern of symptoms of autism collected
retrospectively.
The first three dates will be based on existing records and
both the date  and the relationship of the date to the tim-
ing of MMR vaccination will not be  affected by errors of
memory. First parental concerns about autism may have
occurred many years ago and some error in accurately
remembering the exact date  is to be expected. In addi-
tion, it is possible that parental recall of the date  of onset
of symptoms relative to the timing of MMR vaccination
may be affected  by the recent publicity about a possible
link between MMR and autism. The  proposed link be-
tween MMR vaccine and autism was first publicised in
February  1998. After this date public and media concern
about the possible link may have  affected the likelihood
of a child attending the GP with problems and in  partic-
ular the timing of the presentation relative to MMR vac-
cination. Children  with a date of first symptoms after
February 1998 will be analysed separately  to assess the
effect of possible bias.
For the main analyses the date of onset will be the earli-
est of either the  date of first attendance to the GP with
symptoms potentially relating to a  future diagnosis of
autism or the date of first concerns or symptoms as  re-
corded in the hospital letters.
Assessment of exposure
Exposure to MMR vaccine will be extracted from the GP
electronic record.  This method has two advantages.
Firstly it will avoid recall bias either about  vaccine status
or about the timing of vaccination relative to the onset of
symptoms. Secondly there are good reasons to expect the
vaccine data to be  complete. All general practitioners
participating in the GPRD undertake to  include all med-
ications prescribed or administered in the computerised
record.  In addition, United Kingdom general practition-
ers have a financial incentive to  accurately record child-
hood vaccination status. Finally there is excellent
agreement between prescribing data from the GPRD and
national data from the  Prescription Pricing Authori-
ty[34].
Confounding
Potential confounding factors include those factors
known to affect uptake  of vaccination in the United
Kingdom: the knowledge and attitude of the health  care
provider; presence in the family of a child with a major
illness; social  class; birth order; family size; education ofBMC Public Health (2001) 1:2 http://www.biomedcentral.com/1471-2458/1/2
parents; and religion[39]. Matching on general practice
for one of the control groups  will control for confound-
ing by health care provider. Data on the other  potential
confounding factors will be derived from the question-
naire to parents  of affected children and controls. Very
little is known about factors  associated with autism and
its diagnosis, although a family history of autism  is a
clear risk factor. Age of parental recognition is known to
be associated  with sibship order. We will be collecting
information on these variables in the  questionnaire.
These potential confounders will be controlled for in the
case-control analysis and in the case series analysis.
Analyses
Case-control
Conditional logistic regression will be used to undertake
matched  case-control analyses. We will initially under-
take a series of univariate  analyses. Factors that appear
to be associated with autism (P < 0.2) will  be carried for-
ward to a multivariate model. Likelihood ratio tests will
be used  for all tests of significance. Two analyses will be
carried out. The first will  estimate the odds ratio for the
development of symptoms in specific time  periods after
vaccination with MMR. This method provides an alter-
native  approach to the case series approach outlined be-
low. The second will assess  exposure to MMR vaccine at
any time prior to symptom development. This analysis
differs from the case series approach in that no assump-
tion is required about  the likely interval from vaccina-
tion to disease onset if there is a causal  association.
We will examine the effects of the age matching: compar-
ing the results for  those children very closely matched on
age (for example within 6 months) with  the results for
any children less well matched on age.
The two control groups will be analysed separately. If the
odds ratios  differ substantially, this will indicate that
practice was an important  confounding factor (i.e., that
some practices were better at diagnosing autism  and
also had a higher vaccine coverage). The results for the
two groups will  then be reported separately, but we will
consider the correct result to be that  from the practice
matched group. If the results for the two groups are sim-
ilar,  they will be pooled. In this situation it is possible we
may have  "over-matched" in the practice matched
group, but this will only lead to a loss  of power, not to a
bias in the estimate.
Case series
The case series uses data on affected children only to es-
timate the relative  incidence of clinical events either in a
defined interval after vaccination  compared to time pe-
riods outside this defined interval, or at any time after
vaccination compared with the time period before vacci-
nation [40,41]. The method has been used to estimate
the  relative incidence of febrile convulsions following
DTP and MMR vaccines [42] and was also used in a re-
cent study of the onset of autism  following MMR vaccine
[18]. We will examine periods of 1  month, 2 months, 4
months, 6 months and 1 and 2 years after vaccination.
The  reference period for each individual will consist of
every month from birth up  until February 1998, which
was when the possible link between MMR vaccine and
autism became widely known, excluding the post-vacci-
nation period being  studied. All analyses will be finely
stratified for age, the exact  stratification will depend on
the age distribution of the affected children.
The two approaches estimate different parameters. The
case-control approach  will estimate the odds ratio for
whether children who are vaccinated have an  increased
chance overall of developing autism than children who
are not  vaccinated. The case series will estimate the rel-
ative incidence of autism in  the period following MMR
vaccination.
Power
We estimate we will be able to include a minimum of 400
children with a  diagnosis of autism in the analyses. Over
the entire study period we estimate  the proportion of
children in the control group who will have received
MMR  vaccination to be around 85% [11]. With 5 controls
per  affected child in the case-control analysis we will be
able to detect the  following minimum odds ratios for the
association between autism and MMR  vaccination with
90% power at the 5% significance level: 1.8 if average
MMR  coverage among controls is 85%, or 2.0 if average
MMR coverage among controls  is 90%. For the case se-
ries analysis assuming an 85% vaccine coverage rate (a
conservative estimate), we will have 90% power at the
5% significance level to  detect a minimum relative inci-
dence for autism of 1.6 in the 1 month following  MMR
vaccine.
Ethical approval
The Scientific and Ethical Advisory Group is a central
ethical committee  specially set up by the Department of
Health to oversee use of the GPRD. They  have approved
the study, subject to approval of the questionnaire, as
have the ethics committee of the London School of  Hy-
giene and Tropical Medicine. The use of confidential pa-
tient data in this  study is fully within the recent
guidelines from both the United Kingdom  Medical Re-
search Council [43] and the General Medical  Council
[44] about the use of personal information in  medical re-
search.BMC Public Health (2001) 1:2 http://www.biomedcentral.com/1471-2458/1/2
Discussion
Electronic databases offer several important advantages
for epidemiological  studies of adverse events from vac-
cination. All people affected by the adverse  event (or a
random sample) can be drawn from existing records,
usually avoiding  the problem of ascertainment being
linked to exposure, although bias may not  entirely be re-
moved if people affected were diagnosed after the hy-
pothesis was  known. As controls can be sampled from all
other participants in the database,  biased selection of
controls is less likely to occur. Records of date of  vacci-
nation and onset of symptoms, are also less likely to be
biased, in  particular if they precede the hypothesis com-
ing into public domain. The major  disadvantage of such
databases is that data quality and completeness may not
always be optimal. In particular, all diagnoses of autism
will not have been  made using the same criteria applied
in a consistent manner.
Vaccines are without doubt among the most effective
public health  interventions, but thorough investigation
of suspected adverse effects is  necessary. Case-control
studies using electronic health databases offer a  unique-
ly efficient method for evaluating adverse effects of vac-
cines. However  they also offer scope for bias and
confounding to produce misleading results.  The rigor-
ous validation of all possible diagnoses and the collection
of  additional information by parental questionnaire in
this study will be both  time consuming and expensive,
but we view this as essential to minimise the  possibility
of biased results.
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